No Data
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
The number of A-share flu Concept stocks with limit rise increases: Shijiazhuang Yiling Pharmaceutical and more than 10 other stocks hit the limit rise, while Shandong Xinhua Pharmaceutical is nearing the limit rise.
Gelonghui, January 6 - Currently, it is winter, and the influenza virus is making a comeback, drawing attention to flu medications. In the A-share market, flu Concept stocks have further increased their gains in the afternoon, with more stocks hitting the daily limit. As of now, Sichuan Goldstone has reached the daily limit of 20%, Shanxi Zhendong Pharmaceutical has risen nearly 15%, Xiangxue Pharmaceutical has increased over 11%, Henan Taloph Pharmaceutical Stock, North China Pharmaceutical, Luoxin Pharmaceuticals Group Stock, Xinjiang Bai Hua Cun Pharma Tech, Shandong Lukang Pharmaceutical, Northeast Pharmaceutical Group, Shijiazhuang Yiling Pharmaceutical, Hainan Huluwa Pharmaceutical Group, Harbin Pharmaceutical Group, and Guangdong Zhongsheng Pharmaceutical have all hit the daily limit of 10%, while Shandong Xinhua Pharmaceutical is close to reaching its daily limit.
Shanxi Zhendong Pharmaceutical (300158.SZ): has repurchased a total of 0.3 million shares.
On December 2, Gelonhui reported that Shanxi Zhendong Pharmaceutical (300158.SZ) announced that, as of November 30, 2024, the company has cumulatively repurchased 0.3 million shares of the company through a dedicated securities account for stock repurchases and through centralized competitive trading, accounting for 0.03% of the company's current total share capital. The highest fill price for the repurchase was RMB 5.03 per share, and the lowest fill price was RMB 5.01 per share, with a total transaction amount of RMB 1,506,000 (excluding transaction fees).
Express News | 29 companies disclosed the progress of repurchases, with shanghai zhezhong group, changshu fengfan power equipment, chen ke ming food manufacturing having the highest repurchase proposal amounts.
Shanxi Zhendong Pharmaceutical (300158.SZ): Currently, there is no pharmaceutical for the treatment of dengue fever.
Gelonghui November 6th | Shanxi Zhendong Pharmaceutical (300158.SZ) stated on the investor interaction platform that the company currently does not have pharmaceuticals for treating dengue fever.
Zhendong Pharmaceutical: Report for the third quarter of 2024
